Aytu's EXXUA Launch Gains Traction: Q4 Revenue Up 6.4%, Prescriptions Double
AYTU sits 42% above its 52-week low of $1.65 on elevated volume (7.5× avg).
Summary
Aytu BioPharma reported fiscal Q4 2026 revenue of $16.1M, up 6.4% YoY, beating analyst estimates, driven by EXXUA's first full quarter with $3.9M in sales. EXXUA prescriptions more than doubled sequentially to 3,323, signaling strong early adoption. Full-year revenue fell 13.3% to $57.6M due to generic competition and commercial prioritization of EXXUA, but the company achieved near break-even net loss in Q4 and positive Adjusted EBITDA of $0.5M. Cash stands at $26.3M. Management highlighted broadening prescriber adoption and favorable reimbursement dynamics. The conference call at 4:30 PM ET today may provide further color on EXXUA's trajectory and fiscal 2027 outlook.
At the time of this announcement, AYTU was trading at $2.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.9M. The 52-week trading range was $1.65 to $3.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.